NEW YORK (GenomeWeb News) – TGen Drug Development and Flagship Biosciences today announced a partnership to use their technologies to hasten new drug development.
The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.
Financial and other terms of the deal were not disclosed.
Based in Flagstaff, Ariz., Flagship provides computerized histopathology and expertise in measuring epithelial-mesenchymal transition, when tumor cells become invasive, migratory, and drug resistant.
"Flagship's technology will significantly accelerate our ability to identify biomarkers that could help researchers predict which drug compounds will work best on specific patient cancers," Stephen Gately, president of Scottsdale, Ariz.-based TGen Drug Development, said in a statement.
TGen Drug Development is a non-profit subsidiary of Phoenix-based Translational Genomics Research Institute.